| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-01-09 | Novo Nordisk (Denmark) Glooko (USA - CA) | digital health solutions | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2017-01-09 | Amgen (USA - CA) Immatics (Germany) | T-cell engaging bispecific immunotherapies | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2017-01-09 | Amgen (USA - CA) DaVita (USA - CO) | Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa) | supply services |
Kidney diseases - Metabolic diseases - Renal diseases | Services contract | |
| 2017-01-09 | Aduro Biotech (USA - CA) Merck&Co (USA - NJ) | CRS-207 and pembrolizumab | gastric cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2017-01-09 | Leon-nanodrugs (Germany) | chief executive officer | nomination | Nomination | ||
| 2017-01-09 | Kite Pharma (USA - CA) Daiichi Sankyo (Japan) | axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) and atezolizumab | development licensing commercialisation |
Cancer - Oncology - Rare diseases | Development agreement | |
| 2017-01-09 | Adaptimmune (UK) | nomination | Cancer - Oncology | Nomination | ||
| 2017-01-09 | Chronos Therapeutics (UK) Aptuit (USA - CT) | selective orexin 1 antagonists | addictive behaviours of binge eating and alcohol use disorders | development - collaboration | Addictive diseases - CNS diseases - Mental diseases | Collaboration agreement |
| 2017-01-09 | Allergan (Ireland) Assembly Biosciences (USA - IN) |
|
ulcerative colitis, Crohn's disease, irritable bowel syndromes with diarrhea (IBS-D), with constipation (IBS-C) or mixed (IBS-M) | research - development - licensing | Autoimmune diseases - Inflammatory diseases - Gastrointestinal diseases | Research agreement |
| 2017-01-09 | Orchard Therapeutics (UK) PharmaCell (The Netherlands) | ex-vivo autologous gene therapy products. | production | Rare diseases - Genetic diseases | Production agreement | |
| 2017-01-09 | Ferring Pharmaceuticals (Switzerland) Intralytix (USA - MA) | bacteriophage-based treatments | conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome | development - commercialisation | Gastrointestinal diseases - Digestive diseases - Infectious diseases | Development agreement |
| 2017-01-08 | Amgen (USA - CA) Adaptive Biotechnologies (USA - WA) | NGS-based clonoSEQ Assay | acute lymphoblastic leukemia (ALL) | development commercialisation |
Cancer - Oncology - Diagnostic | Development agreement |
| 2017-01-06 | BMS (USA - NY) GeneCentric Diagnostics (USA - NC) | translational biomarkers for Opdivo® (nivolumab) | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2017-01-06 | Neurocrine Biosciences (USA - CA) | nomination | Neurological diseases | Nomination | ||
| 2017-01-05 | PTC Therapeutics (USA - NJ) Roche (Switzerland) SMA Foundation | Spinal Muscular Atrophy (SMA) programme | spinal muscular atrophy | licensing | Neuromuscular diseases - Rare diseases | Licensing agreement |
| 2017-01-05 | Pieris (Germany) Servier (France) | immune checkpoint inhiitors, immuno-oncology bispecific drug candidates including PRS-332 | collaboration - development - licensing | Cancer - Oncology | Collaboration agreement | |
| 2017-01-05 | Therachon (Switzerland) | chief executive officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-01-05 | Neovacs (France) Sunnybrook Research Institute (Canada) | VEGF Kinoid | colorectal cancer, ovarian cancer | development |
Cancer - Oncology | Development agreement |
| 2017-01-05 | Valneva (France- Austria) MSD Animal Health, a Merck&Co company (USA - NJ) | EB66® cell line | licensing |
Veterinary medicine | Licensing agreement | |
| 2017-01-05 | Valneva (France- Austria) MSD Animal Health, a Merck&Co company (USA - NJ) | EB66® cell line | licensing |
Veterinary medicine | Licensing agreement |
